These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1326625)

  • 1. Characterization of the antagonist activity of the PAF antagonists RP 59227 and WEB 2086 on elicited guinea pig peritoneal macrophages. Evidence for variable affinities and kinetics.
    Turner NC; Wood LJ
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1139-46. PubMed ID: 1326625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
    Floch A; Tahraoui L; Sedivy P; Cavero I
    J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC; Seldon PM; Barnes PJ; Giembycz MA
    Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-activating factor antagonists suppress the generation of tumor necrosis factor-alpha and superoxide induced by lipopolysaccharide or phorbol ester in rat liver macrophages.
    Zhang F; Decker K
    Eur Cytokine Netw; 1994; 5(3):311-7. PubMed ID: 7948767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
    Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial cell-associated platelet-activating factor primes neutrophils for enhanced superoxide production and arachidonic acid release during adhesion to but not transmigration across IL-1 beta-treated endothelial monolayers.
    Hill ME; Bird IN; Daniels RH; Elmore MA; Finnen MJ
    J Immunol; 1994 Oct; 153(8):3673-83. PubMed ID: 7930587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
    Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
    J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of platelet-activating factor induced superoxide anion generation by guinea-pig alveolar macrophages.
    Schmidt J; Lindstaedt R; Szelenyi I
    J Lipid Mediat; 1992 Feb; 5(1):13-22. PubMed ID: 1327265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of degranulation from human eosinophils by platelet-activating factor.
    Kroegel C; Yukawa T; Dent G; Venge P; Chung KF; Barnes PJ
    J Immunol; 1989 May; 142(10):3518-26. PubMed ID: 2541198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
    Koike H; Imanishi N; Natsume Y; Morooka S
    Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in platelet-activating factor receptor mediated Ca++ response between hamster and guinea pig alveolar macrophages.
    Chen J; Giri SN
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1047-58. PubMed ID: 9190835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes.
    Marquis O; Robaut C; Cavero I
    J Pharmacol Exp Ther; 1988 Feb; 244(2):709-15. PubMed ID: 2831350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of platelet activating factor-induced chemiluminescence in guinea-pig peritoneal macrophages in differing states of activation.
    Parnham MJ; Bittner C; Lambrecht G
    Br J Pharmacol; 1989 Oct; 98(2):574-80. PubMed ID: 2819335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RP 59227, a novel PAF receptor antagonist: effects in guinea pig models of airway hyperreactivity.
    Underwood SL; Lewis SA; Raeburn D
    Eur J Pharmacol; 1992 Jan; 210(1):97-102. PubMed ID: 1601051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characterization of platelet-activating factor (PAF)-receptors in neutrophilic and eosinophilic granulocytes].
    Ukena D; Dent G; Chanez P; Barnes PJ; Sybrecht GW
    Pneumologie; 1990 Feb; 44 Suppl 1():531-2. PubMed ID: 2164200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
    Grigoriadis G; Stewart AG
    Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.